glp 1 insulin combo Glucagon-like peptide (GLP-1) fig3.gif

In a prospective study of T2DM patients, six months of liraglutide therapy improved diastolic function and reduced left ventricular mass index [44], while additional echocardiographic studies have reported improvements in global longitudinal strain and left ventricular mass with GLP-1 receptor agonists [45]

Biosocial variation in treatment response to GLP-1s: implications for clinical care and health policy

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins

Clinical trial evidence consistently shows that GLP-1RA therapy results in significant reductions in fat mass, accompanied by smaller but measurable decreases in lean mass